Every parliamentary written question tabled by Daisy Cooper this session, with the full answer and department. See how every department answers, or back to the MP page.
Showing 21–40 of 150 · Department of Health and Social Care
If he will take legislative steps to end the five year rule on investigating sexual misconduct cases before the House rises for summer recess.
The Government is committed to modernising the regulation of all healthcare professionals in the United Kingdom.As a first step, on 24 March 2026, we published our Reforming the General Medical Council legislative framework consultation, which sets out pr...
If he will bring forward from 2032 the New Hospital Programme construction work to redevelop Watford General hospital should capacity become available.
Watford General Hospital is part of Wave 2 of the New Hospital Programme, as set out in the published Plan for Implementation. Pre-construction activity, which includes business case development and enabling works, is expected to commence from 2028, with ...
With reference to the Answer of 14 April 2026 to Question 127101 on Cancer: Vaccination, (a) (i) how many and (ii) which pharmaceutical companies attended the NHS England webinar in 2025, and (b) (
The Cancer Vaccine Launch Pad (CVLP) is a platform that is increasing access and speeding up recruitment to clinical trials for personalised cancer vaccines and other immunotherapies for patients who have been diagnosed with cancer. In 2025, the scope of ...
What assessment he has made of the adequacy of acute mental health inpatient places in Hertfordshire.
Since the pandemic, mental health services in Hertfordshire have faced sustained pressure, including a reliance on out‑of‑area beds, reflecting national trends. A 2023/24 review found local inpatient capacity was significantly below comparable areas.In re...
Pursuant to the Answer of 30 March to Question 119469 on Cancer: Vaccination, how many pharmaceutical companies have been contacted by his Department with details of the expansion of eligibility of the NHS Cancer Vaccine Launch Pad since May 2025.
The Cancer Vaccine Launch Pad (CVLP) is a platform that is increasing access and speeding up recruitment to clinical trials for personalised cancer vaccines and other immunotherapies for patients who have been diagnosed with cancer. In 2025, the scope of the CVLP was expanded beyond personalised cancer vaccines to also include other immunotherapies. NHS England is responsible for the overall delivery of the CVLP and has contracted the Southampton Clinical Trials Unit to manage the day-to-day delivery of the platform. The platform is designed to be company and clinical trial agnostic so any company can contact the CVLP to explore how the platform can support their research. NHS England hosted a webinar with interested pharmaceutical companies in 2025 after the expansion of the scope had been agreed, and continues to engage with companies through multiple avenues, including working with the National Institute for Health and Care Research and the Vaccine Innovation Pathway.
Whether his Department would consider commissioning MenB vaccination programmes through community pharmacy.
The Government is looking to expand the number of vaccines offered in community pharmacies across the country through local, targeted vaccination programmes. This has already started with NHS England commissioning some community pharmacies in the Midlands, North-West, London, and East of England to help deliver the year-round respiratory syncytial virus vaccination programmes to eligible pregnant women, to protect newborns, and adults aged 75 to 79 years old, as well as the year-round Pertussis vaccination programme to eligible pregnant women.NHS England also nationally commissioned community pharmacies to administer flu vaccines for two and three year olds for the first time in autumn 2025. An evaluation will assess whether this use of community pharmacies improves vaccine uptake and helps tackle regional health inequalities, in line with the NHS Vaccination Strategy.The Joint Committee on Vaccination and Immunisation (JCVI) is an expert scientific advisory committee that advises the Government on eligibility for vaccination and immunisation programmes. The JCVI has been consulted on the immediate vaccine response to the outbreak and clinical effectiveness of potential future outbreak response vaccination strategies.On the 17 March my Rt Hon. Friend, the Secretary of State for Health and Social Care, also announced to the House of Commons that he would ask the JCVI to review eligibility for meningococcal B (MenB) vaccination. The JCVI will conduct a full assessment of the cost-effectiveness of a routine adolescent MenB vaccination programme and provide a complete and formal response to my Rt Hon. Friend, the Secretary of State for Health and Social Care, as soon as practicable.The Department, the UK Health Security Agency, and NHS England will continue to ensure arrangements are in place to ensure that everyone who is eligible for MenB vaccination can access vaccinations via appropriate care routes.
What assessment he has made of the role community pharmacy could play in providing a MenB vaccine catch-up service to students and young people at risk.
The Government is looking to expand the number of vaccines offered in community pharmacies across the country through local, targeted vaccination programmes. This has already started with NHS England commissioning some community pharmacies in the Midlands, North-West, London, and East of England to help deliver the year-round respiratory syncytial virus vaccination programmes to eligible pregnant women, to protect newborns, and adults aged 75 to 79 years old, as well as the year-round Pertussis vaccination programme to eligible pregnant women.NHS England also nationally commissioned community pharmacies to administer flu vaccines for two and three year olds for the first time in autumn 2025. An evaluation will assess whether this use of community pharmacies improves vaccine uptake and helps tackle regional health inequalities, in line with the NHS Vaccination Strategy.The Joint Committee on Vaccination and Immunisation (JCVI) is an expert scientific advisory committee that advises the Government on eligibility for vaccination and immunisation programmes. The JCVI has been consulted on the immediate vaccine response to the outbreak and clinical effectiveness of potential future outbreak response vaccination strategies.On the 17 March my Rt Hon. Friend, the Secretary of State for Health and Social Care, also announced to the House of Commons that he would ask the JCVI to review eligibility for meningococcal B (MenB) vaccination. The JCVI will conduct a full assessment of the cost-effectiveness of a routine adolescent MenB vaccination programme and provide a complete and formal response to my Rt Hon. Friend, the Secretary of State for Health and Social Care, as soon as practicable.The Department, the UK Health Security Agency, and NHS England will continue to ensure arrangements are in place to ensure that everyone who is eligible for MenB vaccination can access vaccinations via appropriate care routes.
What assessment he has made of the cost-effectiveness of commissioning a MenB vaccination programme through community pharmacy.
The Government is looking to expand the number of vaccines offered in community pharmacies across the country through local, targeted vaccination programmes. This has already started with NHS England commissioning some community pharmacies in the Midlands, North-West, London, and East of England to help deliver the year-round respiratory syncytial virus vaccination programmes to eligible pregnant women, to protect newborns, and adults aged 75 to 79 years old, as well as the year-round Pertussis vaccination programme to eligible pregnant women.NHS England also nationally commissioned community pharmacies to administer flu vaccines for two and three year olds for the first time in autumn 2025. An evaluation will assess whether this use of community pharmacies improves vaccine uptake and helps tackle regional health inequalities, in line with the NHS Vaccination Strategy.The Joint Committee on Vaccination and Immunisation (JCVI) is an expert scientific advisory committee that advises the Government on eligibility for vaccination and immunisation programmes. The JCVI has been consulted on the immediate vaccine response to the outbreak and clinical effectiveness of potential future outbreak response vaccination strategies.On the 17 March my Rt Hon. Friend, the Secretary of State for Health and Social Care, also announced to the House of Commons that he would ask the JCVI to review eligibility for meningococcal B (MenB) vaccination. The JCVI will conduct a full assessment of the cost-effectiveness of a routine adolescent MenB vaccination programme and provide a complete and formal response to my Rt Hon. Friend, the Secretary of State for Health and Social Care, as soon as practicable.The Department, the UK Health Security Agency, and NHS England will continue to ensure arrangements are in place to ensure that everyone who is eligible for MenB vaccination can access vaccinations via appropriate care routes.
Whether he is taking steps to help improve diagnosis of chronic kidney disease.
NHS England is delivering a comprehensive programme to improve the diagnosis, treatment, and outcomes of people with kidney disease. In 2023, NHS England published a renal services transformation toolkit to support earlier identification of chronic kidney disease and more joined-up services. These changes are intended to make it easier to deliver improvements along the whole patient pathway, including earlier diagnosis and treatment, that can potentially prevent or delay the need for dialysis and transplant further downstream in the pathway.In addition, as set out in the 10-Year Health Plan, we will publish a new cardiovascular disease modern service framework in spring. As part of its development, officials are considering opportunities for earlier identification and diagnosis of chronic kidney disease and are engaging widely to identify the best evidenced interventions.
What steps his Department is taking to help increase the uptake of kidney function tests among at-risk populations in primary care.
Early diagnosis of chronic kidney disease (CKD) is supported through widespread access to blood and urine tests across the National Health Service. Phlebotomy is a key part of this pathway. The NHS delivers over one billion blood tests each year, supporting the diagnosis and monitoring of a wide range of conditions, including CKD. Community diagnostic centres (CDCs) are increasing diagnostic capacity and improving access to testing closer to patients’ homes. Phlebotomy services are currently available in 119 CDCs. CDCs have delivered approximately 1.6 million tests between April 2025 and the end of February 2026. In addition, non-obstetric ultrasound, also used to examine kidneys, is available in 152 CDCs and delivered approximately 1.01 million tests over the same period. NHS England continues to work with integrated care boards to expand diagnostic capacity and improve referral pathways, helping clinicians access the tests needed to support earlier diagnosis and monitoring of long-term conditions, including CKD.
Whether the scope of the NHS Cancer Vaccine Launch pad has been expanded since 2024.
I refer the Hon. Member to the answer given to the Hon. Member for Epsom and Ewell on 24 November 2025 to Question 91780.
Pursuant to the Answer of 4 December 2025 to Question 95904 on Health Professions: Regulation, if he will publish a consultation on secondary legislation to modernise the General Medical Council’s regulatory framework which would enable them to consider fitness to practise concerns arising from allegations of sexual misconduct that are more than five years old during this parliamentary session.
The Government is committed to modernising the regulatory frameworks for all healthcare professionals in the United Kingdom.As a first step, we aim to consult on secondary legislation to modernise the General Medical Council’s (GMC) regulatory framework shortly with a view to laying this legislation before Parliament this year.As part of the consultation, we will be consulting on a reformed fitness to practise process for the GMC.
Pursuant to the Answer of 20 January 2026 to Question 105675 on NHS: Hearing Impairment and Visual Impairment, what steps his Department is taking to improve accessibility of NHS services for Deaf BSL-users following the recommendations of the BSL Advisory Board’s Locked Out report.
We want disabled people’s access to, and experience of, healthcare services to be equitable, effective, and responsive to their needs. The 10-Year Health Plan specifically identifies disabled people as a priority group for the development of neighbourhood health care, offering more holistic ongoing support, noting the health inequalities they face.NHS England is rolling out a Reasonable Adjustment Digital Flag which enables the recording of key information about a disabled patient or client, and the reasonable adjustments to care and treatment that they need, to ensure support can be tailored appropriately and equitably. Under a new information standard, published on 19 December 2025, all publicly funded health and social care service providers must be able to share, read, and write reasonable adjustment data by 30 September 2026. This would include anyone who is a Deaf British Sign Language user, and anyone with another disability.
Pursuant to the Answer of 9 September 2025 to Question 71118 on Prescriptions: Occupational Therapy, what progress he has made on the wider programme of work relating to the medicines responsibilities of occupational therapists.
The Department supports expanding medicines responsibilities for non‑medical professionals where it is safe to do so. Appropriately trained occupational therapists can already supply and administer medicines under patient specific directions or patient group directions.Any changes to medicines responsibilities follow a robust process to ensure patient safety. NHS England develops clinical cases for change with professional bodies, the Commission on Human Medicines provides advice, and, where proposals are progressed, the Department amends the Human Medicines Regulations 2012.The Department has recently concluded a consultation on extending medicines responsibilities for a group of allied health professionals. We are analysing the responses and will consider proposals relating to other professional groups once this work is complete.
Pursuant to the Answer of 28 December 2025 to Question 100476 on Brain: Tumours, what plans the National Institute for Health and Care Research has to undertake horizon scanning of the pharmaceutical and biotech project pipelines to identify potential candidates suitable for developing vaccines for brain tumours in conjunction with the NHS Cancer Vaccine Launch Pad.
The Department invests over £1.6 billion per year in research through the National Institute for Health and Care Research (NIHR). Cancer is a major area of NIHR spending at £141.6 million in 2024/25, reflecting its high priority.The NIHR is continuing to invest in brain tumour research. For example, in December 2025, the NIHR announced the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. The NIHR invested an initial £13.7 million in the consortium with a further £11.7 million announced in January 2026. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer.The NIHR supports cancer vaccine innovation through a coordinated national model, combining the NHS Cancer Vaccine Launch Pad’s clinical prioritisation with the Vaccine Innovation Pathway and the NIHR Industry Hub’s horizon scanning, feasibility, and delivery capability. The NIHR Industry Hub undertakes horizon scanning of pharmaceutical and biotechnology pipelines, as part of its national industry engagement and delivery role, to identify emerging cancer vaccine and immune-therapy platforms, including those with potential relevance to hard-to-treat cancers such as brain tumours. Promising candidates are supported through a single national operating model delivered via the NIHR Industry Hub, which provides a coordinated entry point for industry, structured feasibility assessment, and delivery assurance. Cancer vaccine trials continue to be prioritised and delivered in partnership with the NHS Cancer Vaccine Launch Pad, with accelerated delivery capability provided through the Vaccine Innovation Pathway. Together, this integrated approach ensures that as the science matures, the United Kingdom is able to identify, assess, and rapidly progress suitable cancer vaccine candidates into high-quality clinical trials within the NHS.
If he will extend Business Rates reimbursements to Community Pharmacies.
In the 2025 Autumn Budget, the Government took the hard choices to protect the National Health Service in England and to continue to prioritise reducing waiting times. We have also stepped in to cap bills and help businesses, as part of a £4.3 billion support package.This year, we have also increased funding to community pharmacies to almost £3.1 billion, the largest uplift in funding for any part of the NHS across 2024/25 and 2025/26.The Department will consult Community Pharmacy England on any proposed changes to reimbursement and remuneration of pharmacy contractors for 2026/27 shortly.
Pursuant to the Answer of 20 October to Question 77603 on Brain: Tumours, what steps he plans to take to incentivise pharmaceutical companies involved in developing vaccines for brain tumours to approach the NHS Cancer Vaccine Launch Pad for funding and support.
The Department invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). In the financial year 2024/25, the NIHR’s reported spend on cancer research was over £141.6 million through its research programmes and infrastructure, reflecting cancer’s high priority.The Government is taking measures to boost research into brain tumours. In December 2025, the NIHR announced the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. NIHR is investing an initial £13.7 million with significant further funding due to be awarded in 2026.We also support the Rare Cancers Private Members Bill. This bill aims to incentivise research and investment into treatment by introducing measures to streamline clinical trial recruitment, allow patients to be more easily contacted by researchers, and also mandates a review of orphan drug regulations.The NIHR continues to welcome funding applications for research into any aspect of human health and care, including brain tumours. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.
How organisations providing mental health services to children and young people can engage with the Independent review into mental health conditions, ADHD and autism.
My Rt. Hon. Friend, the Secretary of State for Health and Social Care, has launched an independent review into prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD) and autism. We are deeply concerned that many adults, young people and children with mental health conditions, ADHD and autism have been let down by services and are not receiving timely or appropriate support and treatment. This Government has already taken significant steps to stabilise and improve NHS mental health services but there is much more to do. Transforming the system will take time, but we are committed to delivering a new approach to mental health.Therefore, this independent review will inform our new approach to mental health, so people receive the right support, at the right time and in the right place. Likewise, the review will inform our approach so that people with ADHD and autistic people have the right support in place to enable them to live well in their communities.As this is an independent review, it is for the Chair and Vice-chairs to consider who to consult and the relevant forums for engagement, that are relevant to deliver the terms of reference, set by the Department.
What steps his department is taking to improve (a) awareness, (b) diagnosis and (c) treatment for, pulmonary hypertension.
NHS England commissions specialist services for both adults and children to diagnose and treat pulmonary arterial hypertension. Care is provided through a small number of specialised centres and shared care arrangements with other centres. High-cost drug treatments are delivering improvements in outcomes for this group of patients, as evidenced by the National Pulmonary Hypertension Audit. This audit is funded by NHS England, with further information available at the following link: https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/national-pulmonary-hypertension-audit Clinical guidelines and pathways exist for the investigation of breathlessness, to support the recognition and diagnosis of this rare condition.
Whether his department are taking steps to support the use of the Play Well Toolkit in NHS healthcare settings.
The Department recognises the importance of supporting and maintaining children’s right to play in healthcare settings. Games and active play in all settings build social skills and promote children’s well-being.To support this, in June 2025 NHS England and Starlight, a national charity for children’s play in healthcare, co-published the Play Well Toolkit. The toolkit provides guidance on best practice, and includes a checklist to support the auditing, monitoring, and evaluation of services. NHS England is promoting the Play Well toolkit to managers of health play services across a wide range of settings, including community clinics, emergency departments, children’s hospices, and acute paediatric wards.